Amoeba SAS, a prominent player in the materials sector, specifically within the chemicals industry, has been making significant strides in the development of biological products and services aimed at mitigating microbiological risks across various sectors. Based in Chassieu, France, and incorporated in 2010, the company has carved a niche for itself by leveraging the natural biocidal properties of the living amoeba Willaertia magna C2c Maky. This innovative approach has positioned Amoeba SAS as a leader in the treatment of water, surfaces, and chronic wounds, as well as in the realm of agricultural biocontrol.
The company’s primary exchange listing on the NYSE Euronext Paris underscores its prominence in the European market. Despite the challenges reflected in its financial metrics, such as a negative price-to-earnings ratio of -6.46 and a close price of 0.94 EUR as of February 19, 2026, Amoeba SAS’s market capitalization stands at 64,752,736 EUR. This valuation, while modest, belies the company’s potential for growth and its pivotal role in addressing critical microbiological challenges.
Amoeba SAS’s flagship technology harnesses the biocidal capacity of Willaertia magna C2c Maky to offer solutions for water treatment, surface sanitation, and the management of chronic wounds. This approach not only exemplifies the company’s commitment to leveraging natural processes for environmental and health benefits but also highlights its innovative edge in the chemicals industry. Furthermore, the company’s agricultural biocontrol technology, which targets phytopathogenic microorganisms using lysed amoebae, represents a significant advancement in sustainable agriculture practices.
The fluctuation in Amoeba SAS’s stock price, with a 52-week high of 1.4438 EUR on May 5, 2025, and a low of 0.748 EUR on March 9, 2025, reflects the volatile nature of the market and the challenges faced by companies in the chemicals sector. However, these financial metrics should not overshadow the company’s strategic importance and its contributions to public health and environmental sustainability.
As Amoeba SAS continues to expand its portfolio of biological products and services, its focus on innovation and sustainability positions it well for future growth. The company’s efforts to address microbiological risks in water, health, and plant protection sectors not only demonstrate its commitment to societal well-being but also underscore its potential to lead the way in the development of eco-friendly and effective solutions in the chemicals industry.
In conclusion, Amoeba SAS stands at the forefront of a critical juncture in the chemicals sector, where the demand for sustainable and effective microbiological risk management solutions is at an all-time high. With its unique approach and innovative technologies, the company is well-equipped to meet these challenges head-on, promising a future where biological solutions play a central role in safeguarding public health and the environment.
